Thermo Fisher Hints at Acquisition 'Opportunities' as Q3 Revenue, R&D Spend, and Profits Surge | GenomeWeb
NEW YORK (GenomeWeb News) — Thermo Fisher Scientific today said third-quarter revenues increased over 230 percent as R&D spending rose 52 percent and profit increased more than 300 percent.
 
The company also hinted that the “highly fragmented” market in which it plays “presents opportunities” to make additional acquisitions.
 
Thermo Fisher stressed that last year's results reflect Thermo Electron's operations before its merger with Fisher Scientific last November.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.